Federal opportunity · Solicitation
ClosedDepartment of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
HT9402-26-Q-9404 · Dept of Defense · SAM.gov
Closed. Responses were due Oct 26, 2026, 1:00 PM ET.
- Responses due
- Oct 26, 2026, 1:00 PM ET
- Posted
- Oct 8, 2026
- NAICS code
- 325412 · Pharmaceutical Preparation Manufacturing
- Set-aside
- None
- Place of performance
- San Antonio, TX
- Notice type
- Solicitation
- Solicitation number
- HT9402-26-Q-9404
- Official notice
- View on SAM.gov →
Open opportunities in Pharmaceutical Preparation Manufacturing
- Methylphenidate ERDept of Defense · Due Nov 6, 2026 · Under a day left
- Medical Gas Cylinders, USP, Type I-DOT 3AA SteelDept of Defense · Due Nov 15, 2026 · 9 days left
- Epinephrine InjectorDept of Defense · Due Nov 16, 2026 · 10 days left
- Atropine Auto-InjectorDept of Defense · Due Nov 30, 2026 · 24 days left
- FentanylDept of Defense · No deadline listed
- Morphine Sulfate SolutionDept of Defense · No deadline listed
What the agency was buying
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision.
Show the full description · 191 more wordsShow less
This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
From the official notice on SAM.gov.